Krsnaa Diagnostics Limited has completed the newspaper publication requirements for its postal ballot process seeking shareholder approval for the re-appointment of its Executive Chairman, demonstrating compliance with regulatory disclosure obligations.

Regulatory Compliance and Publication Details

The company submitted newspaper advertisement copies to both BSE Limited and National Stock Exchange of India Limited on March 17, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The postal ballot notice was published in two newspapers to ensure wide dissemination of information to shareholders.

Postal Ballot Process Timeline

The postal ballot process follows the original timeline established in the March 16, 2026 notice, with shareholders eligible to participate in the e-voting process for the Executive Chairman re-appointment.

Executive Chairman Re-appointment Terms

The proposed re-appointment of Mr. Rajendra Khivraj Mutha as Executive Chairman and Whole-time Director covers a comprehensive five-year term with structured remuneration and responsibilities.

The remuneration package includes performance-linked bonuses as determined by the Board of Directors, with total compensation not exceeding limits under Section 197 read with Schedule V of the Companies Act, 2013. Additional perquisites encompass provident fund contributions, gratuity, leave encashment, personal accident insurance, and communication facilities.

Voting Process and Accessibility

The e-voting process is facilitated through NSDL platform with Mr. Dinesh Birla (FCS No.- 7658 and CP No.- 13029), Practicing Company Secretary, appointed as Scrutinizer. The postal ballot notice remains accessible on multiple platforms including the company website, stock exchange platforms, and NSDL's e-voting portal.

Shareholders whose names appear in the Register of Members as on the cut-off date of March 13, 2026, are eligible to participate in the e-voting process. The voting results will be announced within two working days from the conclusion of the e-voting period and will be available across all designated platforms.

Source: None/Company/INE08LI01020/f2936a35-1243-4a16-9214-dd7061681424.pdf

Krsnaa Diagnostics Limited's Board of Directors has officially approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for a five-year term, following recommendations from the Nomination and Remuneration Committee. The decision was formalized during a board meeting held on February 22, 2026, with proper regulatory disclosures filed under SEBI regulations.

Board Meeting Outcome and Regulatory Filing

The board meeting, which commenced at 18:30 Hrs. (IST) and concluded at 21:10 Hrs. (IST), resulted in the formal approval of Mr. Mutha's re-appointment as Whole-time Director and Chairman, designated as Executive Chairman. The company has filed the necessary disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with both stock exchanges.

Re-appointment Terms and Conditions

The Board of Directors has approved Mr. Mutha's re-appointment in accordance with the Companies Act, 2013, SEBI (LODR) Regulations, 2015, and other applicable regulatory provisions. The appointment remains subject to shareholder approval through postal ballot and includes liability to retire by rotation.

Leadership Profile and Industry Expertise

Mr. Rajendra Khivraj Mutha brings over two decades of specialized expertise in pharmacy and diagnostics to his executive role. As a certified Pharmacist accredited by the Maharashtra State Pharmacy Council, he leverages extensive industry knowledge to drive the company's strategic vision and operational excellence.

Beyond operations, he spearheads impactful outreach initiatives focused on community health, women, and children, earning recognition as a changemaker in Indian healthcare. He also leads the company's Corporate Social Responsibility programmes, championing initiatives that uplift underserved communities and reinforce the company's role as a trusted healthcare partner.

Governance and Compliance Standards

The re-appointment maintains proper corporate governance standards, with Mr. Mutha confirmed as not being related to any other Directors on the company's Board. He meets all regulatory compliance requirements and is not debarred from holding directorial positions by SEBI or any other regulatory authority, as confirmed in compliance with SEBI guidelines dated June 14, 2018.

The formal regulatory disclosure has been submitted to both BSE Limited and National Stock Exchange of India Limited, ensuring full transparency and compliance with listing obligations. This re-appointment underscores the board's confidence in Mr. Mutha's ability to continue leading the company's growth trajectory in the competitive healthcare diagnostics market.